07:24 AM EDT, 07/08/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Tuesday that the US Food and Drug Administration has accepted for review its new drug application for ET-600.

The company said ET-600 is its patented formulation of desmopressin oral solution for the treatment of central diabetes insipidius.

The FDA has set a target action date of Feb. 25, 2026 and Eton Pharmaceuticals ( ETON ) Chief Executive Offiver Sean Brynjelsen said the company has already started commercial preparation activities for a potential product launch in Q1 2026.

Shares of Eton Pharmaceuticals ( ETON ) were up 8% in recent premarket activity Tuesday.